New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
07:05 EDTRXIIRXi Pharmaceuticals granted patent for fibrosis treatment technology
RXi Pharmaceuticals has been granted a patent by the USPTO on its unique self-delivering RNAi compounds, for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF, including RXI‑109, for the treatment of fibrotic disorders. The patent will expire in 2029.
News For RXII From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
07:10 EDTRXIIRXi Pharmaceuticals signs exclusive global license for second Phase 2 compound
Subscribe for More Information
December 17, 2014
07:10 EDTRXIIRXi Pharmaceuticals begins Phase 2 study of scar revision surgery candidate
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use